Teva Pharmaceutical Industries (BSP:T1EV34) Long-Term Debt : R$88,985 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Teva Pharmaceutical Industries Long-Term Debt?

Teva Pharmaceutical Industries's Long-Term Debt for the quarter that ended in Dec. 2023 was R$88,985 Mil.

Teva Pharmaceutical Industries's quarterly Long-Term Debt increased from Jun. 2023 (R$90,754 Mil) to Sep. 2023 (R$91,341 Mil) but then declined from Sep. 2023 (R$91,341 Mil) to Dec. 2023 (R$88,985 Mil).

Teva Pharmaceutical Industries's annual Long-Term Debt declined from Dec. 2021 (R$122,242 Mil) to Dec. 2022 (R$100,203 Mil) and declined from Dec. 2022 (R$100,203 Mil) to Dec. 2023 (R$88,985 Mil).

Teva Pharmaceutical Industries Long-Term Debt Historical Data

The historical data trend for Teva Pharmaceutical Industries's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Long-Term Debt Chart

Teva Pharmaceutical Industries Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

100,814.73

116,944.18

122,241.97

100,202.88

88,985.27

Teva Pharmaceutical Industries Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Debt	Get a 7-Day Free Trial															100,202.88	102,442.75	90,754.48	91,341.26	88,985.27

Teva Pharmaceutical Industries (BSP:T1EV34) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Teva Pharmaceutical Industries Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Teva Pharmaceutical Industries (BSP:T1EV34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (BSP:T1EV34) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

TEVJF:USA TEVA:USA TEVA:Mexico TEVA:Israel 0LER:UK TEV:Germany TEVA:Austria

Address

124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020

Website

https://www.tevapharm.com

Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.

Teva Pharmaceutical Industries (BSP:T1EV34) Headlines

No Headlines